Secukinumab

Form: Injection

Strength: 150 mg/mL

Reference Brands: Cosentyx

Category: Osteoporosis

Secukinumab (Cosentyx®) is a leading IL-17A monoclonal antibody approved for the treatment of moderate-to-severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. It is available as a 150 mg/mL prefilled syringe or autoinjector, designed for convenient subcutaneous administration. Trusted globally under the Cosentyx brand by Novartis, it is used in dermatology and rheumatology settings across the US and EU. Manufactured under GMP/ICH-compliant standards, Secukinumab is ideal for B2B pharmaceutical buyers, including hospitals, clinics, and specialty pharmacies. Contact us for bulk export, regulatory support, and competitive pricing.